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The annexins are family of calcium-regulated phospholipid-binding proteins with diverse roles in cell biology. Individual annexins have
been implicated in tumour development and progression, and in this investigation a range of annexins have been studied in colorectal
cancer. Annexins A1, A2, A4 and A11 were identified by comparative proteomic analysis to be overexpressed in colorectal cancer.
Annexins A1, A2, A4 and A11 were further studied by immunohistochemistry with a colorectal cancer tissue microarray containing
primary and metastatic colorectal cancer and also normal colon. There was significant increase in expression in annexins A1
(P¼0.01), A2 (Po0.001), A4 (Po0.001) and A11 (Po0.001) in primary tumours compared with normal colon. There was
increasing expression of annexins A2 (P¼0.001), A4 (P¼0.03) and A11 (P¼0.006) with increasing tumour stage. An annexin
expression profile was identified by k-means cluster analysis, and the annexin profile was associated with tumour stage (P¼0.01) and
also patient survival. Patients in annexin cluster group 1 (low annexin expression) had a better survival (log rank¼5.33, P¼0.02) than
patients in cluster group 2 (high annexins A4 and A11 expression). In conclusion, this study has shown that individual annexins are
present in colorectal cancer, specific annexins are overexpressed in colorectal cancer and the annexin expression profile is associated
with survival.
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The annexins are a multigene family of calcium-regulated
phospholipid-binding proteins (Gerke and Moss, 2003; Gerke
et al, 2005). The annexins are classified into five groups (A–E),
and within each of these groups, individual annexins are identified
numerically. Annexins in group A are human annexins, with group
B referring to animal annexins without human orthologs, group C
to fungi and moulds, group D to plants and group E to protists
(Liemann and Huber, 1997; Rand, 2000; Hayes and Moss, 2004;
Rescher and Gerke, 2004; Lim and Pervaiz, 2007). The character-
istic annexin structural motif is a 70-amino-acid repeat, called the
annexin repeat. Four annexin repeats packed into an a-helical disk
are contained within the C-terminal polypeptide core (Gerke and
Moss, 2003). While all annexins share this core region, the
N-terminal varies widely between annexins, and it is this diversity
of N-terminal amino-acid sequence that gives the individual
annexins their functional differences and biological activities
(Gerke and Moss, 2003; Gerke et al, 2005). There are 12 human
annexin subfamilies (A1–A11 and A13) that have been found to
have various intra- and extracellular roles in a range of cellular
processes such as cell signalling, ion transport, cell division and
apoptosis (Gerke and Moss, 2003; Gerke et al, 2005).
All annexins share an ability to bind to negatively charged
phospholipid membranes in a calcium-dependent manner. This
property is found within the annexin core motif where the
calcium- and membrane-binding sites are located. Annexins bind
to the cytosolic surface of the plasma membrane and to organelle
membranes such as the Golgi apparatus. This binding can be
reversed by the removal of calcium, freeing the annexin from the
phospholipid membrane. However, the functional significance of
their reversible membrane-binding ability remains unknown in
many annexins, although in some it is thought to be important
for vesicle aggregation and membrane organisation (Liemann and
Huber, 1997; Rand, 2000; Rescher and Gerke, 2004; Lim and
Pervaiz, 2007). Although all annexins share this binding property,
there is variation in calcium sensitivity and phospholipid
specificity between individual annexins. For example, within one
cell there can be differences in the distribution of annexins, with
annexin A1 having an endosomal localisation, A2 to be found in
cytosol and A4 being associated with the plasma membrane
(Liemann and Huber, 1997).
Some annexins are capable of calcium-independent binding and
several have roles in vesicle aggregation. Annexins A1, A2 and A11
function in cooperation with other calcium-binding proteins to
form complexes while annexins A1, A2 and A5 interact with
cytoskeletal proteins. Many annexins are involved in exocytic and
endocytic pathways and some have roles in ion channel regulation
(Gerke and Moss, 2003). Extracellularly, annexin A1 has a role in
controlling the inflammatory response while annexin A2 is present
on the external surface of endothelial cells, where it may act as a
receptor for ligands, including plasminogen and tissue plasminogen
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sactivator (Diaz et al, 2004; Roda et al, 2006). Extracellular annexin
A5 is thought to be involved in the anticoagulation process (Rand,
2000; Hayes and Moss, 2004).
Annexins have been implicated in several disease processes,
including inflammation and neoplasia (Rand, 2000). Alterations in
the expression of individual annexins have been associated with
tumorigenesis in several types of tumour. Loss of annexin A1 has
been found to be an early event in oesophageal squamous cell
carcinoma, and it may function as a tumour suppressor in the
development of this type of tumour (Paweletz et al, 2000).
Expression of annexin A1 has also been associated with poorly
differentiated oesophageal tumours of higher tumour stage (Hu
et al, 2004). Together, these studies suggest that dysregulation of
annexin A1 loss is important in oesophageal tumour development
and progression. Other types of cancer in which the expression of
annexin A1 has been shown to be altered include pancreatic
adenocarcinoma (Bai et al, 2004), where it was found to show
increased expression in the majority of tumours, renal cell
carcinoma (Zimmermann et al, 2007), prostate adenocarcinoma
(Patton et al, 2005), breast cancer (Shen et al, 2006) and B-cell
non-Hodgkin’s lymphoma (Vishwanatha et al, 2004).
Other annexins have also been implicated in tumorigenesis.
Overexpression of annexin A2 has been found in renal cell cancer,
where it is associated with tumour stage (Zimmermann et al,
2004a), invasive breast cancer (Sharma et al, 2006) and sarcomas,
including both soft tissue sarcomas (Syed et al, 2007) and
osteosarcomas (Gillette et al, 2004). There is increased expression
of annexin A4 in renal clear cell carcinoma (Zimmermann et al,
2004b). In prostate cancer, decreased expression of annexin A4 has
been shown to correlate with worsen pathological stage (Xin et al,
2003), and loss of annexin A7 has been associated with metastatic
and local recurrences of hormone refractory prostate cancer
(Srivastava et al, 2001).
However, the annexins have received no significant study in
colorectal cancer and in this study we used comparative proteomic
analysis to identify proteins that are overexpressed in colorectal
cancer, compared with morphologically normal colorectal mucosa.
The annexins A1, A2, A4 and A11 were identified as four such
proteins. In order to further define the roles played by these
proteins in colorectal neoplasia, their expression and cellular
localisation was studied by immunohistochemistry in a large series
of colorectal cancers represented within a colorectal cancer tissue
microarray.
MATERIALS AND METHODS
Proteomics
Two-dimensional gel electrophoresis and matrix-assisted laser
desorption ionisation time of flight mass spectrometry (MALDI-
TOF MS) on normal colon and colorectal cancer were performed
as previously described (Lawrie et al, 2004; Dundas et al, 2005;
Coghlin et al, 2006). Proteins were solubilised from Dukes C
adenocarcinoma tissue samples and patient-matched morphologi-
cally normal colorectal mucosa (n¼10 pairs of tumour and
normal samples). Two-dimensional gel electrophoresis was
performed using 3–10pI immobilon strips with proteins being
separated according to charge, and subsequently molecular weight.
Following completion of the electrophoresis, gels were stained with
Coomassie blue to visualise protein spots. The spots were excised
from the gels and peptide mass mapping was performed using a
PerSeptive Biosystems Voyager-DE STR mass spectrometer. The
masses of the tryptic fragments were determined and entered into
the MS-Fit database-searching program (http://prospector.ucsf.edu/
ucsfhtml14.0/msfit.htm). The database was restricted to searching
for human proteins, but no restrictions were placed on either
molecular weight or isoelectric point. To ensure that proteins were
accurately identified, a significant difference in statistical score
(MOWSE score) between proteins ranked first and second in the
results had to be obtained.
Antibodies
A polyclonal antibody to annexin A4 was produced in our own
laboratory. An immunising peptide was designed, which took into
consideration both antigenicity and hydrophilicity. Furthermore, a
blast search was used to determine that the peptide was unique to
annexin A4 (SVLAYRNTA corresponding to amino acids 39–47 of
annexin A4), thus ensuring no crossreactivity with other proteins.
The annexin IV peptide conjugated to ovalbumin was used to
immunise rabbits subsequently followed with four boosters, with a
protocol we have previously used for the development of other
antibodies (Kumarakulasingham et al, 2005). Nine weeks after the
initial booster, rabbits were bled and serum was tested by ELISA
using the peptide as an immunogen. The sera that showed the
highest antibody titre were also tested by immunoblotting using
whole-cell lysates. Immunoblotting showed that the antibody
recognised a protein at the expected molecular size for annexin A4.
Monoclonal antibodies to annexins A1, A2, A7 and A11 were
bought from BD Biosciences (Oxford, UK).
Tumour samples and tissue microarray construction
All cases were selected from the Aberdeen colorectal tumour bank.
In total, 268 patients were involved in this study; in each case, a
diagnosis of primary colorectal cancer had been made, and the
patients had undergone elective surgery for primary colorectal
cancer, in Aberdeen, between 1994 and 2003. The Aberdeen
colorectal tumour bank is linked to a comprehensive set of
clinicopathological data, including age, gender, site of primary
tumour, degree of tumour differentiation and tumour stage. The
data for the patients included in this study are detailed in Table 1.
Complete follow-up ranging from 0 to 144 months was available
for all patients, and the mean patient survival was 91 months. At
the time of censoring the data, there had been 106 (39.6%) deaths
in the patient group. The tumour samples were submitted to the
Table 1 Clinicopathological data of the patients in this study
Characteristic Number (%)
Gender
Male 135 (50.4%)
Female 133 (49.6%)
Age (years)
Mean 68
Range 33–92
o70 127 (47.4%)
X70 141 (52.6%)
Dukes stage
A 53 (19.8%)
B 104 (38.8%)
C 111 (41.4%)
Tumour site
Proximal colon 95 (35.4%)
Distal colon 97 (36.2%)
Rectum 76 (28.4%)
Tumour differentiation
Well 10 (3.7%)
Moderate 228 (85.1%)
Poor 30 (11.2%)
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The tumour excision specimens were fixed in formalin, represen-
tative blocks were embedded in wax and sections were stained with
haematoxylin and eosin. Permission for this study was obtained
from the Grampian Research Ethics Committee.
A colorectal cancer tissue microarray was constructed as
described (Dundas et al, 2005; Kumarakulasingham et al, 2005).
The tumours within the array were representative of the
distribution of anatomical locations and the Dukes stages found
in colorectal cancers within this population. The tissue microarray
contained primary colorectal cancer (Dukes A¼53, Dukes B¼104
and Dukes C¼111). In addition, it contained lymph node
metastases and morphologically normal colonic mucosal samples.
The lymph node metastases were from the corresponding Dukes C
cases (n¼111). Each normal sample (n¼52) was acquired from at
least 10cm distant from the tumour as previously described
(Kumarakulasingham et al, 2005). Using a steel Menghini needle, a
representative 1.6mm core of tissue was taken from each donor
block and arrayed into the recipient wax block. In order to check
the histopathological diagnosis and the adequacy of tissue
sampling, a section from each microarray was stained with
haematoxylin and eosin and examined by light microscopy.
Immunohistochemistry
Annexin immunohistochemistry was carried out using a Dako
autostainer (Dako, Ely, UK) as previously described (Dundas et al,
2005; Coghlin et al, 2006). Sections (4mm) of the tissue microarray
were dewaxed, rehydrated and an antigen retrieval step performed
when required. The antigen retrieval step consisted of micro-
waving the sections in 0.01 M citrate buffer at pH 6.0 for 20min in
an 800W microwave oven operated at full power. The sections
were then allowed to cool to room temperature. Primary antibody
appropriately diluted (Table 2) in antibody diluent (Dako) was
applied for 60min at room temperature, washed with buffer
(Dako) followed by peroxidase blocking for 5min (Dako), followed
by a single 2-min buffer wash. Prediluted peroxidase polymer-
labelled goat anti-mouse/rabbit secondary antibody (Envisiont,
Dako) was applied for 30min at room temperature, followed by
further washing with buffer to remove unbound antibody. Sites of
peroxidase activity were then demonstrated with diaminobenzi-
dine as the chromogen applied for three successive 5min periods.
Finally, sections were washed in water, lightly counterstained with
haematoxylin, dehydrated and mounted. Omitting the primary
antibody from the immunohistochemical procedure and replacing
it with antibody diluent or non-immune rabbit serum acted as
negative controls.
The sections were evaluated by light microscopic examination,
and cellular localisation and intensity (negative¼0, weak¼1,
moderate¼2, strong¼3) of immunostaining in each section were
assessed by two observers (RD and GIM).
Statistical analysis
Comparison of expression of individual annexins in normal colon,
colon cancer and lymph node metastasis was performed with the
Mann–Whitney U-test. The chi-square (w
2) test was used to
compare annexin expression with tumour stage while the annexin
expression profile was determined by k-means cluster analysis.
The relationship of patient survival and annexin expression was
determined using the method of Kaplan–Meier and the log-rank
test. Cox-multivariate analysis was used to determine the relative
significance of individual clinicopathological factors, annexin
expression and patient survival. All the statistical analyses were
performed using SPSS v15 for Windows XPt (SPSS UK Ltd,
Woking, UK).
RESULTS
Proteomics
Comparative proteomic analysis using two-dimensional gel
electrophoresis identified certain protein spots that were repre-
sented in the colorectal cancer samples but not in the normal
colorectal mucosal samples (Figure 1). Protein spots of interest
were digested and the masses of the tryptic fragments were
determined using MALDI-TOF MS. These masses were entered
into MS-Fit, which identified annexins A1, A2, A4 and A11 with a
high degree of significance. The MOWSE score (a measure of the
identity of the protein) for annexin A1 was 1.68eþ003, annexin A2
was 6.53eþ005, annexin A4 was 1.52eþ008 and annexin A11 was
6.67eþ005.
Immunohistochemistry
Primary colorectal cancer The annexins with the exception of
annexin A7 showed increased immunostaining in primary
tumours in comparison to normal colon (Figures 2 and 3). Weak
staining was seen for all annexins varying from 0.4 to 25.9% of
tumours. Moderate and strong tumour cell staining was seen in
Table 2 Details of annexin antibodies used in this study
Antibody Source Type Antigen retrieval Dilution
Annexin A1 BD Bioscience Monoclonal Yes 1/100
Annexin A2 BD Bioscience Monoclonal Yes 1/100
Annexin A4 Own laboratory Polyclonal Yes 1/500
Annexin A7 BD Bioscience Monoclonal Yes 1/100
Annexin A11 BD Bioscience Monoclonal Yes 1/400
100 kDa A
B
100 kDa
15 kDa
15 kDa
pl3 pl10
A4 A1 A2
A11
Figure 1 Two-dimensional gels of (A) colorectal cancer and (B) normal
colon mucosa. The circles labelled A1, A2, A4 and A11 correspond to the
protein spots annexins A1, A2, A4 and A11, respectively (Coomassie blue-
stained two-dimensional electrophoresis gel).
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GH
IJ
Figure 2 The immunohistochemical localisation of annexins in normal colon and colorectal cancer. Normal colon (A, C, E, G and I) and colorectal
cancer (B, D, F, H and J). Annexin A1 (A and B), annexin A2 (C and D), annexin A4 (E and F), annexin A7 (G and H) and annexin A11 (I and J).
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sannexins A1, A2, A4 and A11. More tumours showed strong
staining for A1, A2 and A4 than showed moderate staining. The
highest percentage of strong staining was seen in annexin A4, with
64.9% of tumours showing strong staining. However, for annexin
A11, moderate staining was observed in 33.3% of tumours
compared to 31.1% of tumours that showed strong staining
(Figures 2 and 3). There was significant increase in expression in
annexins A1 (P¼0.01), A2 (Po0.001), A4 (Po0.001) and A11
(Po0.001) in primary tumours compared with normal colon
(Figure 3). There was increased expression of annexins A2, A4 and
A11 with increasing tumour stage (Table 3).
Lymph node metastasis The annexins except annexin A7 showed
immunoreactivity in lymph node metastasis. Annexins A2 and A11
showed the greatest percentage of weak staining at 20.7 and 29%,
respectively, with less tumours showing moderate and strong
staining for these annexins. As in normal and primary tumours,
annexin A4 showed the greatest percentage of strong staining at
62.3% of tumours. Comparing the expression of annexins in lymph
node metastasis with the corresponding primary tumours showed
that there was a significant decrease in expression of annexin A11
(P¼0.01) in lymph node metastasis compared with corresponding
primary colorectal cancers (Figure 4).
Annexin expression profile and clinicopathological factors
To further dissect the role of annexin expression in colorectal
cancer, the annexin expression profile was determined. To identify
the relationship of the overall annexin profile within tumours,
k-means cluster analysis was performed and this identified four
clusters or groups with distinct annexin profiles (Table 4). The
annexin profile was associated with Dukes stage (w
2¼16.76,
P¼0.01). The annexin expression profile was also associated with
survival. Patients in annexin cluster group 1 (low annexin
expression) had a better survival (log rank¼5.33, P¼0.02;
Figure 5) than patients in cluster group 2 (high annexin A4 and
A11 expression). The mean survival in group 1 was 96 months
(95% CI: 80–113 months) and in group 2 was 72 months (95% CI:
62–82 months). However, there was no relationship between the
expression of individual annexins and patient survival and also the
annexin profile was not an independent marker of prognosis
following multivariate analysis.
DISCUSSION
The annexins are a multigene family of calcium-dependent
phospholipid-binding proteins (Gerke and Moss, 2003; Hayes
and Moss, 2004; Gerke et al, 2005). There are 12 human annexins
each of which shows a cell- and tissue-type-specific pattern of
expression. Some of the annexins have been well characterised
while less is known about the biology of some of the other
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Figure 3 The mean intensity of expression of individual annexins in
normal colon, primary colorectal cancer and lymph node metastasis.
Table 3 The relationship of annexin expression and tumour (Dukes) stage
Annexin v
2 P-value Interpretation
A1 5.48 0.484 There is no relationship of annexin A1 expression and tumour stage
A2 23.6 0.001 There is increased expression of annexin A2 with increasing tumour stage
A4 7.1 0.029 There is increased expression of annexin A4 with increasing tumour stage
A7 NA NA NA
A11 10.2 0.006 There is increased expression of annexin A11 with increasing tumour stage
NA, not available. The expression of individual annexins as determined by immunohistochemistry in each tumour stage (Dukes A vs Dukes B vs Dukes C) was compared to
assess the trend in annexin expression (i.e., increase, decrease, no change) with advancing tumour stage.
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Figure 4 Comparison of the mean intensity of annexin expression in
Dukes C primary tumours and corresponding lymph node metastasis.
Table 4 Annexin cluster membership
Annexin cluster group
Annexin Group 1 Group 2 Group 3 Group 4
A1 Negative Negative Negative Strong
A2 Negative Negative Strong Weak
A4 Weak Strong Moderate Strong
A7 Negative Negative Negative Negative
A11 Weak Strong Strong Moderate
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sannexins. Functions of the annexins include vesicle aggregation
and ion channel regulation as well as roles in cell cycle regulation,
cell signalling, cell differentiation and as extracellular receptors.
Several of the annexins have been linked to the pathogenesis of a
variety of disease processes, including the development and
progression of several different types of cancer, and from these
studies there appears to be tumour-type-specific alterations in the
expression of individual annexins (Paweletz et al, 2000; Gerke and
Moss, 2003; Xin et al, 2003; Bai et al, 2004; Gillette et al, 2004;
Hayes and Moss, 2004; Hu et al, 2004; Vishwanatha et al,
2004; Patton et al, 2005; Sharma et al, 2006; Shen et al, 2006;
Zimmermann et al, 2004a,b, 2007; Syed et al, 2007). However, the
annexin profile has not previously been investigated in individual
tumour types. Furthermore, while there has been a range of studies
of individual annexin expression in specific types of primary
tumours, there have been no significant previous studies of
annexin expression in metastasis. In addition, more recently
individual annexins have been proposed as putative tumour
biomarkers and potential therapeutic targets in cancer (Oh et al,
2004; Falsey et al, 2006; Wozny et al, 2007).
The expression and cellular localisation of annexins have
received very little previous study in colorectal cancer, with only
annexin A2 having been investigated (Emoto et al, 2001). In this
study, comparative proteomic analysis utilising two-dimensional
gel electrophoresis and mass spectrometry identified four annex-
ins, namely A1, A2, A4 and A11 to be overexpressed in colorectal
cancer when compared with normal colon. The expression profile
of these annexins was then validated on a large cohort of well-
characterised colorectal cancer samples, and the immunohisto-
chemical component of the study was also extended to include a
further annexin, annexin A7, as it has also been implicated in
tumorigenesis (Srivastava et al, 2001). The relationship of annexin
expression with clinicopathological parameters, in particular,
tumour stage and overall patient survival was also investigated.
Annexins A1, A2, A4 and A11 were found to be overexpressed in
primary colorectal cancer and expression of the annexins A2, A4
and A11 all increased significantly with advancing tumour stage.
These findings suggest that annexins A2, A4 and A11 have an
important role in the progression of colorectal cancer. In support
of these findings, several studies have implicated individual
annexins in tumorigenesis. Annexin A1 has been reported to show
altered expression in a variety of different cancers, including
oesophageal cancer (Paweletz et al, 2000; Hu et al, 2004; Wang
et al, 2006), pancreatic cancer (Bai et al, 2004) and hairy cell
leukaemia (Falini et al, 2004). In oesophageal adenocarcinoma, the
tumour cell expression of annexin A1 has been associated with
poor prognosis (Wang et al, 2006). Furthermore, annexin A1 has
been found to be overexpressed in immortalised colorectal cell
lines (Guzman-Aranguez et al, 2005). This annexin has also a
potential role in tumour invasion and metastasis, as inhibition of
annexin A1 using siRNA resulted in a significant reduction of cell
invasion using an in vitro assay on an immortalised colorectal
cancer cell line (Babbin et al, 2006).
Annexin A2 shows increased expression in several type of
cancer, including renal cell cancer (Zimmermann et al, 2004a),
breast cancer (Sharma et al, 2006) and sarcomas (Gillette et al,
2004; Syed et al, 2007), and there are several possible mechanisms
by which annexin A2 may be involved in tumour progression.
Annexin A2 interacts with tissue-type plasminogen activator and
disruption of this interaction resulted in decreased tumour cell
invasion (Rand, 2000; Diaz et al, 2004; Sharma et al, 2006).
Annexin A2 is also known to form a complex with cathepsin B that
can initiate proteolytic cascades and degrade extracellular matrix
proteins. These functions may enhance tumour cell detachment,
invasion and motility and thus promote tumour invasion and
metastasis (Mai et al, 2000). Cell-surface annexin A2 also acts as a
receptor for tenascin C, a key extracellular matrix protein involved
in epithelial–stromal interactions, and increased annexin A2
expression is associated with progression in pancreatic neoplasia
from pancreatic intraepithelial neoplasia through to invasive
pancreatic carcinoma (Esposito et al, 2006). Recently, it has also
been shown that the production of matrix metalloproteinase 1, a
key enzyme promoting colorectal cancer invasion (Murray et al,
1996), can be mediated by annexin A2. Inhibition of annexin A2
was associated with loss of production of this matrix-degrading
enzyme (Zhang et al, 2007).
Renal clear cell carcinoma also shows overexpression of annexin
A4 and this seems to be related to the metastatic potential of this
type of tumour (Zimmermann et al, 2004b). Annexin A4 had a
distinct subcellular localisation in tumour cells and this was linked
to loss of cell-to-cell adhesion and increased tumour cell
dissemination (Zimmermann et al, 2004b). Additionally, it has
been demonstrated that overexpressed annexin A4 promotes cell
migration in a model tumour system (Zimmermann et al, 2004b),
which correlates with our observation that annexin A4 expression
increased as tumour stage progressed, such findings are indicative
that annexin A4 is implicated in tumour spread. Annexin A4 is
known to form complexes with protein kinase C, and there are 10
isoforms of protein kinase C that have roles in cancer progression
(metastasis) and some of these isoforms have been shown to be
overexpressed in colorectal cancer (Gokmen-Polar et al, 2001). It
could be through association with protein kinase C isoforms that
annexin A4 has an effect on the pathogenesis of colorectal cancer.
Annexin A4 has also been shown to be overexpressed in a
paclitaxel-resistant cell line and, moreover, overexpression of
annexin A4 in this cell line resulted in a four-fold increase in
paclitaxel resistance also indicating a role for annexins in
anticancer drug resistance (Han et al, 2000).
Annexin A11 was overexpressed in colorectal cancer and increased
expression correlated with more advanced tumour stage. Annexin
A11 is implicated as being involved in cell growth (Farnaes and
Ditzel, 2003) and a reduction in annexin A11 expression using RNAi
stops cell division (Tomas et al, 2004). However, annexin A11
expression was decreased in metastasis, suggesting further dys-
regulation of this protein with tumour progression and possibly
indicating that the tumour microenvironment plays a role in
regulating annexin A11, although the specific mechanisms regulating
this annexin remain to be elucidated.
Annexin A7 expression was not detected in either normal colon
or colorectal cancer, whereas annexin A7 has been proposed as a
putative tumour suppressor gene in prostate cancer (Srivastava
et al, 2001) and that high expression of annexin A7 is associated
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Figure 5 Patient survival in annexin cluster groups. There is a significant
difference in survival between cluster group 1 (low annexin expression)
and cluster group 2 (high annexins A2 and A11 expression, log rank¼5.33;
P¼0.02).
Annexins and colorectal cancer
R Duncan et al
431
British Journal of Cancer (2008) 98(2), 426–433 & 2008 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
swith poor prognosis in breast cancer (Srivastava et al, 2004), thus
providing further evidence that there is tumour-type-specific
regulation and expression of individual annexins.
In conclusion, this study has shown that annexins A1, A2, A4
and A11 are significantly overexpressed in colorectal cancer and
that the overexpression of annexins A2, A4 and A11 showed a
significant correlation with increasing tumour stage. The overall
expression profile of annexins was associated with survival in
colorectal cancer, indicating collectively that annexin expression
may contribute to outcome and this would be consistent with the
putative roles of annexins in some of the cellular processes that led
to tumour invasion. These annexins may also represent tumour
biomarkers and potential therapeutic targets (Oh et al, 2004; Falsey
et al, 2006; Wozny et al, 2007).
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